Chapter: General Anesthesia — Chapter 14 — Module: GA-03 — CNS and Cardiovascular Effects of Inhalational Anesthetics Tier: Foundational Recall (16 questions)
1. Inhalational anesthetic agents act on two principal neurotransmitter receptor systems to suppress central nervous system activity. Which of the following correctly states the direction of effect on each receptor system?
A) They inhibit GABA-A receptors, reducing inhibitory neurotransmission, and activate NMDA receptors, increasing excitatory neurotransmission — the net result is paradoxical excitation at low concentrations
B) They activate GABA-A receptors and activate NMDA receptors simultaneously; both effects are excitatory and together produce the initial excitement phase seen at sub-anesthetic concentrations
C) They inhibit both GABA-A and NMDA receptors equally; the anesthetic state results from global suppression of all receptor-mediated neurotransmission without selectivity for inhibitory or excitatory systems
D) They potentiate GABA-A receptors — enhancing inhibitory neurotransmission — and inhibit NMDA receptors — reducing excitatory neurotransmission; both actions converge to suppress cortical and subcortical neuronal excitability
E) They potentiate NMDA receptors — the principal excitatory receptor — while leaving GABA-A receptors unaffected; unconsciousness results from NMDA-mediated calcium influx overwhelming neuronal firing capacity
ANSWER: D
Rationale:
Option D is correct. Inhalational anesthetics act on the two principal receptor systems in opposite and complementary directions. They potentiate GABA-A receptors — the main inhibitory receptor class in the brain — increasing chloride conductance and hyperpolarizing neurons. They simultaneously inhibit NMDA receptors — a major class of excitatory glutamate receptors — reducing calcium and sodium influx and decreasing excitatory synaptic transmission. Both actions converge on the same outcome: reduced neuronal excitability and suppressed cortical and subcortical activity.
Option A: Option A is incorrect because it reverses both effects; volatile agents potentiate (not inhibit) GABA-A receptors and inhibit (not activate) NMDA receptors.
Option B: Option B is incorrect because GABA-A receptor activation is inhibitory, not excitatory; and NMDA receptors are inhibited, not activated, by volatile agents.
Option C: Option C is incorrect because volatile agents do not inhibit GABA-A receptors; their action on the inhibitory system is potentiation, not inhibition — and the selectivity between the two systems is real and well established.
Option E: Option E is incorrect because NMDA receptors are excitatory receptors that are inhibited — not potentiated — by inhalational agents; potentiation of an excitatory receptor would produce stimulation, not anesthesia.
2. Volatile anesthetic agents produce dose-dependent changes on the electroencephalogram (EEG). Which of the following correctly describes the agent-specific difference in the depth of EEG suppression achievable at clinically used concentrations?
A) Isoflurane is distinguished from halothane and sevoflurane by its ability to produce complete electrical silence — an isoelectric EEG — at clinically achievable concentrations; halothane and sevoflurane produce progressive EEG slowing but do not reliably achieve isoelectric EEG at clinical doses
B) Sevoflurane is the only volatile agent capable of producing an isoelectric EEG; isoflurane and halothane plateau at burst suppression regardless of concentration because of their lower lipid solubility
C) All volatile agents produce identical EEG trajectories at equivalent MAC fractions; the progression from alpha slowing through burst suppression to isoelectric EEG occurs at the same concentrations for every halogenated agent
D) Halothane produces the deepest EEG suppression among the volatile agents, achieving isoelectric EEG at 1 MAC; isoflurane produces only burst suppression at equivalent concentrations because it acts primarily on NMDA receptors rather than GABA-A receptors
E) EEG suppression by volatile agents plateaus at burst suppression for all agents; true isoelectric EEG is not achievable with any inhaled anesthetic and requires barbiturate administration as an adjunct
ANSWER: A
Rationale:
Option A is correct. The EEG trajectories of volatile agents share a common direction — progressive slowing with increasing concentration — but differ in the depth of suppression achievable at clinically used doses. Isoflurane is distinguished by its ability to produce complete electrical silence (isoelectric EEG) at clinically achievable concentrations, a property that is specifically exploited during deliberate hypotension or temporary vessel occlusion in aneurysm surgery to maximize the brain's ischemia-tolerable interval. Halothane produces more gradual EEG slowing and does not reliably produce burst suppression, let alone isoelectric EEG, at clinical doses. Sevoflurane produces dose-dependent EEG suppression comparable to isoflurane in many respects, but isoflurane remains the more established agent specifically for isoelectric EEG induction.
Option B: Option B is incorrect because sevoflurane is not the sole agent capable of isoelectric EEG; isoflurane holds this distinction as the most studied and established agent for this purpose, and lipid solubility is not the determining factor for EEG suppression depth.
Option C: Option C is incorrect because the EEG trajectories are not identical at equivalent MAC fractions; agent-specific differences in the depth and character of EEG suppression are well established, with isoflurane's isoelectric capability being the key distinguishing feature.
Option D: Option D is incorrect because halothane does not produce isoelectric EEG at 1 MAC or at any clinical dose; it produces less EEG suppression than isoflurane at equivalent MAC fractions, not more.
Option E: Option E is incorrect because isoelectric EEG is achievable with isoflurane at clinically used concentrations; the statement that all agents plateau at burst suppression is pharmacologically incorrect.
3. Minimum alveolar concentration (MAC) is the standard potency measure for inhalational anesthetic agents. Which of the following precisely and correctly defines MAC?
A) The alveolar concentration of an inhalational agent at which 50% of patients lose consciousness in response to verbal command under standardized conditions
B) The alveolar concentration of an inhalational agent at which 50% of patients show no response to a standard surgical skin incision — defined as the minimum concentration required for surgical analgesia
C) The alveolar concentration of an inhalational agent at which 50% of patients do not move in response to a standard noxious stimulus — defined as a surgical skin incision — under standardized conditions at one atmosphere
D) The alveolar concentration of an inhalational agent required to produce amnesia in 50% of patients, serving as the threshold below which awareness under anesthesia becomes clinically significant
E) The minimum blood concentration of an inhalational agent — measured as the end-tidal partial pressure — at which 50% of patients tolerate endotracheal intubation without hemodynamic response
ANSWER: C
Rationale:
Option C is correct. MAC is defined as the minimum alveolar concentration of an inhalational agent at which 50% of patients do not move in response to a standard noxious stimulus — specifically a surgical skin incision — under standardized conditions at one atmosphere of pressure. Three elements of this definition require precision: the endpoint is lack of movement (a spinal cord-mediated reflex), not loss of consciousness or amnesia; the stimulus is a standardized surgical skin incision; and the measurement is alveolar concentration at equilibrium, reflecting brain partial pressure. MAC is an ED50 for the movement suppression endpoint specifically.
Option A: Option A is incorrect because MAC is not defined by loss of consciousness in response to verbal command; that endpoint is captured by a separate measure sometimes called MAC-awake (approximately 0.3 to 0.5 MAC), which is substantially lower than MAC.
Option B: Option B is incorrect because MAC is not defined as the minimum concentration required for surgical analgesia; analgesia is a separate endpoint, and the movement suppression that defines MAC is mediated at the spinal cord level, not through supraspinal analgesic pathways.
Option D: Option D is incorrect because MAC is not defined by the amnesia endpoint; amnesia occurs at concentrations well below 1 MAC, and MAC-amnesic is a separate and lower value than MAC.
Option E: Option E is incorrect because MAC is defined by the skin incision movement endpoint, not by tolerance of endotracheal intubation; the concentration required to suppress hemodynamic responses to intubation is captured by MAC-intubation or MAC-BAR (blockade of adrenergic response), which is typically 1.5 to 2 times MAC.
4. At equivalent minimum alveolar concentration (MAC) fractions, which of the following correctly ranks the cerebral blood flow (CBF) increase produced by halothane compared to isoflurane and sevoflurane?
A) Isoflurane produces the greatest CBF increase among the volatile agents at equivalent MAC fractions, followed by sevoflurane, then halothane; this ranking explains why isoflurane is avoided in patients with elevated intracranial pressure
B) Halothane produces the greatest increase in CBF at equivalent MAC fractions — with increases of 200% or more above baseline reported at 2 MAC — while isoflurane and sevoflurane produce more modest increases of approximately 20 to 40% above baseline at 1 MAC in normocapnic patients
C) All three agents — halothane, isoflurane, and sevoflurane — produce equivalent CBF increases at equivalent MAC fractions; differences in clinical ICP effects are explained entirely by differences in their effects on cerebral metabolic rate, not by differences in vasodilatory potency
D) Sevoflurane produces the greatest CBF increase because of its rapid uptake kinetics; halothane and isoflurane produce equivalent and smaller increases because their higher blood-gas solubility limits the rate of cerebrovascular exposure
E) Halothane and isoflurane produce equivalent CBF increases; sevoflurane is unique in producing minimal CBF change at clinical concentrations, which is why it is the preferred volatile agent for all neuroanesthetic procedures
ANSWER: B
Rationale:
Option B is correct. Among the volatile halogenated anesthetic agents, halothane produces the greatest increase in cerebral blood flow at equivalent MAC fractions. Studies have reported CBF increases of 200% or more above baseline at 2 MAC halothane — a substantially greater vasodilatory effect than the newer agents. Isoflurane and sevoflurane produce more modest CBF increases, typically 20 to 40% above baseline at 1 MAC in normocapnic patients. Desflurane's CBF effects are intermediate and similar to isoflurane. This ranking — halothane > desflurane ≈ isoflurane ≈ sevoflurane — is clinically important because it explains why halothane imposes greater intracranial pressure risk per MAC than the newer agents, and why isoflurane or sevoflurane are the preferred volatile agents when a volatile technique is used in neurosurgical patients.
Option A: Option A is incorrect because it places isoflurane at the top of the CBF ranking; halothane, not isoflurane, produces the greatest CBF increase at equivalent MAC fractions.
Option C: Option C is incorrect because the CBF increases are not equivalent across agents at equivalent MAC fractions; the differences in vasodilatory potency are real, well documented, and clinically significant independent of CMRO2 effects.
Option D: Option D is incorrect because uptake kinetics (blood-gas solubility) do not determine vasodilatory potency; the ranking of CBF effects is determined by direct pharmacodynamic properties on cerebrovascular smooth muscle, not by the rate of drug delivery.
Option E: Option E is incorrect because halothane and isoflurane do not produce equivalent CBF increases — halothane produces substantially greater increases — and sevoflurane is not unique in producing minimal CBF change; it produces modest but real increases similar to isoflurane.
5. A key clinical strategy in neuroanesthesia involves using controlled hyperventilation to counteract the cerebral vasodilation produced by volatile anesthetic agents. Which of the following correctly describes the status of CO2 vasomotor reactivity — the cerebrovascular response to changes in arterial CO2 — during inhalational anesthesia?
A) CO2 vasomotor reactivity is abolished by all volatile anesthetic agents at concentrations above 0.5 MAC, which is why hyperventilation is ineffective at reducing cerebral blood flow during volatile maintenance and osmotic agents must be used instead
B) CO2 vasomotor reactivity is selectively preserved by sevoflurane but abolished by isoflurane and desflurane; this property makes sevoflurane uniquely suitable for neuroanesthetic techniques that rely on hyperventilation for brain bulk management
C) CO2 vasomotor reactivity is enhanced by volatile anesthetic agents — they sensitize cerebrovascular smooth muscle to CO2 changes — so hyperventilation produces greater CBF reduction under volatile anesthesia than in the awake state
D) CO2 vasomotor reactivity is partially but not fully preserved during volatile anesthesia; a PaCO2 reduction of 10 mmHg produces only a 5% reduction in CBF under volatile anesthesia, compared to 20 to 30% in the awake state, limiting hyperventilation's utility
E) CO2 vasomotor reactivity is preserved during inhalational anesthesia; the cerebrovascular constriction produced by hypocapnia and the vasodilation produced by hypercapnia continue to operate during volatile maintenance, making hyperventilation an effective strategy for counteracting anesthetic-induced cerebral vasodilation
ANSWER: E
Rationale:
Option E is correct. CO2 vasomotor reactivity — the intrinsic sensitivity of the cerebral vasculature to changes in arterial CO2 partial pressure — is preserved during inhalational anesthesia with volatile agents. This is a pharmacologically important distinction from cerebral autoregulation, which is impaired by volatile agents in a dose-dependent fashion. The preservation of CO2 reactivity means that reducing PaCO2 through controlled hyperventilation causes cerebral vasoconstriction and reduces CBF even during volatile agent maintenance — a reduction of approximately 20 to 30% per 10 mmHg fall in PaCO2, broadly similar to the awake state. This is the physiological basis for the clinical practice of moderate hyperventilation (target PaCO2 30 to 35 mmHg) to blunt anesthetic-induced cerebral vasodilation in neurosurgical patients.
Option A: Option A is incorrect because CO2 vasomotor reactivity is preserved, not abolished, during volatile anesthesia; hyperventilation remains effective at reducing CBF during volatile maintenance and is routinely used for this purpose.
Option B: Option B is incorrect because CO2 reactivity is not selectively preserved by sevoflurane and abolished by isoflurane and desflurane; it is preserved across all the commonly used volatile agents.
Option C: Option C is incorrect because CO2 reactivity is preserved at approximately its baseline level, not enhanced; volatile agents do not sensitize the cerebrovascular response to CO2.
Option D: Option D is incorrect because the magnitude of CO2-mediated CBF change during volatile anesthesia is not reduced to only 5% per 10 mmHg PaCO2 change; the vasoreactivity response is preserved at a clinically meaningful level approximating the awake response.
6. Which of the following correctly and completely characterizes the epileptogenic profile of enflurane, including the concentration threshold, the condition that potentiates it, and the clinical contraindication that follows?
A) Enflurane produces epileptiform EEG activity at any concentration in patients with a pre-existing seizure disorder but is safe in patients without epilepsy; it is contraindicated only in known epileptics, and the seizure risk is not altered by changes in arterial CO2
B) Enflurane has mild epileptogenic potential at concentrations above 3 MAC that is clinically insignificant at surgical doses; it is contraindicated only in patients with refractory status epilepticus, not in patients with well-controlled epilepsy
C) Enflurane causes seizures by blocking GABA-A receptors at high concentrations, an effect that is potentiated by hypercapnia because elevated CO2 further reduces inhibitory tone; it is contraindicated in any patient receiving benzodiazepine therapy because of pharmacodynamic antagonism
D) Enflurane produces high-amplitude EEG spike-and-wave complexes and can induce generalized tonic-clonic seizures at concentrations above approximately 2 MAC; this epileptogenic potential is markedly potentiated by hypocapnia, which lowers the seizure threshold through cerebral vasoconstriction and neuronal alkalosis; enflurane is formally contraindicated in patients with epilepsy and unsuitable for procedures requiring cortical monitoring
E) Enflurane is epileptogenic at all concentrations in a dose-independent fashion; the seizure risk is fixed regardless of inspired concentration, and the only reliable prevention is avoidance of the agent entirely in any patient who will undergo general anesthesia
ANSWER: D
Rationale:
Option D is correct. Enflurane is the only volatile anesthetic agent with clinically documented epileptogenic potential, and its profile has three defining features that must be stated together to be clinically useful. First, the concentration threshold: epileptiform activity appears at inspired concentrations above approximately 2 MAC — it is not a risk at standard maintenance concentrations of 0.5 to 1.5 MAC in most patients, but becomes significant as concentration rises. Second, the potentiating condition: hypocapnia — low arterial PaCO2, as produced by controlled hyperventilation — markedly amplifies the epileptogenic risk. The mechanism involves cerebral vasoconstriction reducing cerebral blood flow and neuronal alkalosis from falling CO2, both of which lower the seizure threshold. This creates a clinically dangerous interaction because hyperventilation is a standard neuroanesthetic maneuver for brain bulk management. Third, the contraindication: enflurane is formally contraindicated in patients with epilepsy and should not be used for neurosurgical procedures requiring cortical monitoring where seizure activity would confound the monitoring signal.
Option A: Option A is incorrect because enflurane's epileptogenic potential applies to patients without epilepsy as well — it can induce seizures in neurologically normal patients at high concentrations — and hypocapnia, not normocapnia or hypercapnia, potentiates the risk.
Option B: Option B is incorrect because the threshold is approximately 2 MAC, not 3 MAC, and the clinical contraindication extends to all patients with epilepsy, not only those with refractory status epilepticus.
Option C: Option C is incorrect because enflurane does not cause seizures through GABA-A blockade — it actually has some GABA-A potentiating properties at lower concentrations; its epileptogenicity involves abnormal cortical excitation at high concentrations, and hypercapnia is not the potentiating condition — hypocapnia is.
Option E: Option E is incorrect because enflurane's epileptogenicity is concentration-dependent, not dose-independent; the risk is specifically associated with high concentrations above approximately 2 MAC, not with standard maintenance dosing.
7. At the EEG pattern of burst suppression, volatile anesthetic agents have achieved the maximum degree of cerebral metabolic suppression attainable through electrical inactivation. Which of the following correctly states the approximate magnitude of this maximum suppression and the reason why deeper anesthesia cannot reduce cerebral oxygen consumption further?
A) Approximately 50 to 60% of basal cerebral oxygen consumption is suppressed at burst suppression; the remaining approximately 40% supports cellular housekeeping functions — principally ion pump activity (particularly the Na/K-ATPase) and membrane maintenance — that are not driven by neuronal electrical activity and are therefore not suppressible by anesthetic-induced electrical silencing
B) Approximately 80 to 90% of basal cerebral oxygen consumption is suppressed at burst suppression; the remaining 10 to 20% is consumed by astrocytes and oligodendrocytes, which are pharmacologically insensitive to volatile agents because they lack GABA-A receptors
C) Approximately 30 to 40% of basal cerebral oxygen consumption is suppressed at burst suppression; deeper anesthesia above 2 MAC continues to reduce CMRO2 by suppressing glial metabolism, eventually approaching complete metabolic arrest at 3 MAC
D) Cerebral oxygen consumption is reduced by approximately 50 to 60% at burst suppression, and further reduction is prevented by the maximum capacity of the Na/K-ATPase pump — once the pump reaches its minimum activity rate, it cannot be further inhibited by anesthetic agents and maintains a fixed metabolic floor
E) Approximately 50 to 60% suppression is achieved at burst suppression; the remaining oxygen consumption is entirely devoted to maintaining the resting membrane potential of neurons and would be eliminated if the agent could produce true isoelectric EEG, but no volatile agent can achieve isoelectric EEG at any concentration
ANSWER: A
Rationale:
Option A is correct. At burst suppression, CMRO2 is reduced by approximately 50 to 60% from awake baseline — the maximum achievable through electrical inactivation of neuronal firing. The remaining approximately 40% of cerebral oxygen consumption represents the metabolic floor: cellular housekeeping processes that are not coupled to neuronal electrical activity. These include the activity of the Na/K-ATPase pump, which must continuously pump sodium out of and potassium into cells to maintain resting membrane potential regardless of whether action potentials are being generated, and membrane maintenance processes. Because these metabolic demands are not driven by electrical firing, suppressing electrical activity further — even to complete isoelectric silence — does not reduce them. This defines a ceiling on the neuroprotective benefit of metabolic suppression: increasing anesthetic depth beyond burst suppression provides no additional metabolic protection.
Option B: Option B is incorrect because the suppression at burst suppression is approximately 50 to 60%, not 80 to 90%; and the characterization that residual consumption is exclusively glial and due to absence of GABA-A receptors is incorrect — the residual floor is present across all cell types and reflects non-electrical metabolic demands.
Option C: Option C is incorrect because burst suppression represents approximately 50 to 60% suppression, not 30 to 40%; and deeper anesthesia beyond burst suppression does not continue to reduce CMRO2 — the ceiling is reached at burst suppression, not at some higher concentration.
Option D: Option D is incorrect because the mechanism of the metabolic floor is not the maximum capacity of the Na/K-ATPase being reached; the pump is working at its minimum necessary rate to maintain membrane integrity, and this rate is not a pharmacological maximum of the pump's capacity.
Option E: Option E is incorrect because isoelectric EEG is achievable with isoflurane at clinically used concentrations; and the description that the remaining oxygen consumption would be eliminated by isoelectric EEG is incorrect — the housekeeping floor persists even at complete electrical silence.
8. The Monro-Kellie doctrine governs intracranial pressure dynamics. Which of the following correctly identifies the three compartments within the cranial vault and accurately describes the primary compensatory mechanism that normally accommodates a small increase in intracranial blood volume without a significant rise in intracranial pressure?
A) The three compartments are brain parenchyma, extracellular fluid, and arterial blood; the primary compensatory mechanism is active vasoconstriction of cerebral arterioles, which reduces arterial inflow to offset the volume increase
B) The three compartments are neurons, glial cells, and venous blood; the primary compensatory mechanism is glial cell shrinkage in response to osmotic shifts created by the volume increase
C) The three compartments are brain parenchyma, cerebrospinal fluid (CSF), and blood; the primary compensatory mechanism is displacement of CSF out of the cranial vault and into the spinal subarachnoid space, reducing CSF volume to accommodate the increase in blood volume
D) The three compartments are brain parenchyma, cerebrospinal fluid, and interstitial fluid; the primary compensatory mechanism is reabsorption of interstitial fluid by the blood-brain barrier, reducing extracellular brain water to offset the blood volume increase
E) The three compartments are cerebral cortex, brainstem, and cerebrospinal fluid; the primary compensatory mechanism is increased CSF production by the choroid plexus, which raises the CSF pressure to resist the expanding blood volume
ANSWER: C
Rationale:
Option C is correct. The Monro-Kellie doctrine holds that the cranial vault is a rigid, fixed-volume compartment whose contents must sum to a constant. The three compartments are brain parenchyma (approximately 80% of intracranial volume), cerebrospinal fluid (approximately 10%), and blood (approximately 10%). When intracranial blood volume increases — as occurs with volatile-anesthetic-induced cerebral vasodilation — the primary compensatory mechanism is displacement of CSF from the cranial subarachnoid space and ventricular system into the spinal subarachnoid space. The spinal dural sac is compliant and can accommodate this displaced volume without a significant rise in pressure. This CSF buffering mechanism is finite: once it is exhausted (as in patients with mass lesions, hydrocephalus, cerebral edema, or any condition that has already consumed the CSF reserve), any further increase in blood volume produces a disproportionate rise in intracranial pressure.
Option A: Option A is incorrect because arterial blood is not a distinct Monro-Kellie compartment separate from brain parenchyma; the correct compartments are parenchyma, CSF, and all intracranial blood (arterial and venous); and arterial vasoconstriction is not the primary compensatory mechanism — CSF displacement is.
Option B: Option B is incorrect because neurons and glial cells are not separate Monro-Kellie compartments; brain parenchyma is a single compartment; and glial cell shrinkage is not the primary compensation for increased intracranial blood volume.
Option D: Option D is incorrect because interstitial fluid is not a distinct Monro-Kellie compartment; and blood-brain barrier reabsorption of interstitial fluid is not the primary or rapid compensatory mechanism for acute blood volume increases.
Option E: Option E is incorrect because the Monro-Kellie compartments are not defined by anatomical brain regions such as cortex and brainstem; and increased CSF production would worsen ICP, not compensate for it — compensation requires reducing another compartment's volume.
9. Cerebral autoregulation maintains relatively constant cerebral blood flow across a range of cerebral perfusion pressures. Which of the following correctly states the normal autoregulatory range in healthy adults and accurately describes how volatile anesthetic agents alter this mechanism?
A) The normal autoregulatory range is approximately 30 to 120 mmHg CPP; volatile agents enhance autoregulation by stabilizing cerebrovascular tone through GABA-A receptor activation in vascular smooth muscle, making the autoregulatory plateau broader and more resistant to perturbation
B) The normal autoregulatory range is approximately 50 to 150 mmHg CPP; volatile agents impair cerebral autoregulation in a dose-dependent fashion, with substantial attenuation at concentrations of 1 MAC or above, shifting the cerebrovascular response toward a pressure-passive state in which CBF varies directly with CPP
C) The normal autoregulatory range is approximately 50 to 150 mmHg CPP; volatile agents do not affect autoregulation but abolish CO2 vasoreactivity, so that the CBF changes observed during volatile anesthesia reflect CO2 changes from altered ventilation rather than impaired autoregulation
D) The normal autoregulatory range is approximately 70 to 180 mmHg CPP in all adults regardless of baseline blood pressure history; volatile agents selectively impair the upper limit of autoregulation while preserving the lower limit, so hypotension is well tolerated but hypertension causes obligatory ICP elevation
E) The normal autoregulatory range is approximately 50 to 150 mmHg CPP; volatile agents impair autoregulation only at concentrations above 2 MAC; at concentrations of 0.5 to 1.5 MAC — the range used for surgical maintenance — autoregulation is fully intact and CBF remains pressure-independent
ANSWER: B
Rationale:
Option B is correct. In healthy normotensive adults, cerebral autoregulation maintains relatively constant CBF across a CPP range of approximately 50 to 150 mmHg. Within this range, cerebrovascular resistance adjusts automatically to compensate for MAP changes. Volatile anesthetic agents impair this autoregulatory mechanism in a dose-dependent fashion. At concentrations of 1 MAC or above, all volatile agents substantially attenuate the cerebrovascular resistance adjustments that underlie autoregulation, shifting the CPP-CBF relationship toward a pressure-passive state. In this state, CBF varies more directly with CPP: hypotension reduces CBF proportionally (risking hypoperfusion), and hypertension increases CBF proportionally (risking ICP elevation in non-compliant brains). This impairment distinguishes volatile agents from propofol, which preserves autoregulation better at clinical infusion rates.
Option A: Option A is incorrect because the lower limit of normal autoregulation is approximately 50 mmHg, not 30 mmHg; and volatile agents impair, not enhance, autoregulation.
Option C: Option C is incorrect because while CO2 vasoreactivity is preserved during volatile anesthesia, autoregulation is impaired — these are distinct mechanisms; the claim that volatile agents do not affect autoregulation is pharmacologically incorrect.
Option D: Option D is incorrect because the normal autoregulatory lower limit is approximately 50 mmHg, not 70 mmHg for all adults; and volatile agents impair the entire autoregulatory mechanism, not selectively the upper limit.
Option E: Option E is incorrect because autoregulatory impairment by volatile agents occurs at concentrations of 1 MAC or above — not only above 2 MAC; the characterization that autoregulation is fully intact at standard maintenance concentrations (0.5 to 1.5 MAC) is incorrect.
10. All volatile anesthetic agents reduce mean arterial pressure, but halothane's mechanism is pharmacologically distinct from that of isoflurane, sevoflurane, and desflurane. Which of the following correctly identifies halothane's primary mechanism of MAP reduction and the associated change in systemic vascular resistance?
A) Halothane reduces MAP through potent peripheral vasodilation — producing the greatest reduction in systemic vascular resistance among the volatile agents — while cardiac output is relatively preserved through baroreceptor-mediated reflex tachycardia
B) Halothane reduces MAP through a combination of direct sinoatrial node inhibition causing profound bradycardia and simultaneous peripheral vasodilation; both mechanisms contribute equally to the MAP reduction
C) Halothane reduces MAP through selective pulmonary vasoconstriction that increases right ventricular afterload, reducing right ventricular output and secondarily reducing left ventricular preload and cardiac output; systemic vascular resistance is unaffected
D) Halothane and isoflurane reduce MAP through identical mechanisms — both are primarily peripheral vasodilators; the difference between them is only in the potency of vasodilation, with halothane being less potent than isoflurane at equivalent MAC fractions
E) Halothane reduces MAP primarily through direct myocardial depression — reducing contractility, stroke volume, and cardiac output — while systemic vascular resistance is maintained or even increased; this mechanism is distinct from isoflurane and sevoflurane, which reduce MAP primarily through peripheral vasodilation
ANSWER: E
Rationale:
Option E is correct. Halothane's primary cardiovascular mechanism is direct myocardial depression: it reduces myocardial contractility, leading to decreased stroke volume and cardiac output. Importantly, systemic vascular resistance is maintained or may even increase under halothane, in contrast to isoflurane, sevoflurane, and desflurane (at stable concentrations), which reduce MAP primarily through peripheral vasodilation — lowering SVR while cardiac output is relatively preserved through baroreceptor-mediated compensatory tachycardia. This mechanistic distinction is clinically critical: patients with impaired left ventricular function tolerate isoflurane-induced MAP reduction (which preserves cardiac output by reducing afterload) far better than halothane-induced MAP reduction (which further depresses an already-compromised cardiac output). Halothane also tends to produce bradycardia through direct depression of sinoatrial node automaticity and increased vagal sensitivity, further reducing cardiac output.
Option A: Option A is incorrect because halothane is not the most potent peripheral vasodilator — isoflurane holds that distinction; halothane's mechanism is myocardial depression with maintained SVR, not vasodilation with preserved cardiac output.
Option B: Option B is incorrect because while halothane does produce bradycardia, this occurs through sinoatrial node depression and vagal sensitization, not through a mechanism equivalent to peripheral vasodilation; and the primary mechanism of MAP reduction is myocardial depression, not the bradycardia.
Option C: Option C is incorrect because halothane does not primarily act through pulmonary vasoconstriction; its cardiovascular effects are on the systemic myocardium and systemic vasculature.
Option D: Option D is incorrect because halothane and isoflurane do not share the same mechanism of MAP reduction; this is one of the most pharmacologically important distinctions in this drug class — halothane depresses the myocardium while isoflurane primarily dilates peripheral vessels.
11. Among the volatile halogenated anesthetic agents, which produces the greatest reduction in systemic vascular resistance at equivalent MAC fractions, and how does this property compare to halothane's primary cardiovascular effect?
A) Halothane produces the greatest SVR reduction among the volatile agents; isoflurane produces intermediate vasodilation; sevoflurane and desflurane produce the least peripheral vasodilation and rely more on myocardial depression for their MAP-lowering effect
B) Sevoflurane produces the greatest SVR reduction and is therefore the most appropriate agent for deliberate hypotensive anesthesia; isoflurane and desflurane produce equivalent and lesser degrees of vasodilation
C) All volatile agents produce equivalent reductions in SVR at equivalent MAC fractions; the clinical differences in cardiovascular effect between agents are entirely attributable to differences in their degree of myocardial depression, not differences in peripheral vasodilation
D) Isoflurane is the most potent peripheral vasodilator among the volatile agents, producing the greatest reduction in SVR at equivalent MAC fractions; halothane, by contrast, produces the least peripheral vasodilation — its predominant cardiovascular mechanism is myocardial depression rather than vasodilation
E) Desflurane produces the greatest SVR reduction among volatile agents, particularly during rapid concentration increases, because the sympathetic surge it triggers paradoxically causes peripheral vascular bed dilation through beta-2 adrenergic receptor activation
ANSWER: D
Rationale:
Option D is correct. Among the volatile halogenated anesthetic agents, isoflurane is the most potent peripheral vasodilator, producing the greatest reduction in systemic vascular resistance at equivalent MAC fractions. Sevoflurane and desflurane produce intermediate reductions in SVR. Halothane occupies the opposite end of this spectrum — it produces the least peripheral vasodilation, and its predominant cardiovascular mechanism is direct myocardial depression with maintained or even increased SVR. This creates the fundamental pharmacological distinction between halothane and the other agents: halothane reduces MAP by reducing cardiac output (myocardial depression), while isoflurane and its congeners reduce MAP primarily by reducing SVR (vasodilation) with relative preservation of cardiac output. This distinction directly governs agent selection in patients with cardiac disease.
Option A: Option A is incorrect because it places halothane at the top of the vasodilatory ranking; halothane is in fact the least vasodilatory volatile agent, with its cardiovascular effects dominated by myocardial depression.
Option B: Option B is incorrect because sevoflurane does not produce the greatest SVR reduction; isoflurane holds that distinction among the currently used volatile agents, and sevoflurane's effects are intermediate.
Option C: Option C is incorrect because volatile agents do not produce equivalent SVR reductions at equivalent MAC fractions; the differences in peripheral vasodilatory potency are real, pharmacologically established, and clinically significant.
Option E: Option E is incorrect because desflurane's sympathetic surge during rapid concentration increases produces tachycardia and hypertension — indicating vasoconstriction and increased SVR, not vasodilation; the sympathomimetic effect causes alpha-adrenergic-mediated vasoconstriction, not beta-2-mediated vasodilation.
12. Desflurane has a cardiovascular property that is unique among the volatile agents and is specifically associated with one particular pattern of administration. Which of the following correctly identifies this property, the condition required to trigger it, and the cardiovascular profile of desflurane when that condition is absent?
A) Desflurane produces a marked sympathetic discharge — with tachycardia and hypertension — specifically when its inspired concentration is increased rapidly, particularly from below to above 1 MAC; at stable maintenance concentrations, desflurane's cardiovascular profile is similar to isoflurane, with MAP reduction mediated primarily through peripheral vasodilation
B) Desflurane produces a marked sympathetic discharge at all inspired concentrations above 0.5 MAC regardless of whether the concentration is being changed or held constant; this sustained sympathetic activation distinguishes it from all other volatile agents and requires routine beta-blockade during maintenance
C) Desflurane produces a sympathetic surge specifically during the recovery phase when the inspired concentration is rapidly decreased; during maintenance at stable concentrations it produces bradycardia and hypotension more severe than any other volatile agent
D) Desflurane's sympathetic surge property is triggered by the total cumulative dose of desflurane administered, not by the rate of concentration change; patients who receive more than 2 MAC-hours of desflurane invariably develop tachycardia and hypertension regardless of how gradually the concentration was increased
E) Desflurane triggers sympathetic discharge when combined with nitrous oxide above 50% inspired concentration; when used without nitrous oxide, desflurane behaves identically to sevoflurane at all concentration ranges and produces no sympathetic activation
ANSWER: A
Rationale:
Option A is correct. Desflurane's sympathetic surge property is uniquely linked to the rate of concentration change, not to the absolute concentration or the duration of exposure. When the inspired desflurane concentration is increased rapidly — particularly from below 1 MAC to above 1 MAC — a marked sympathetic catecholamine discharge occurs, producing tachycardia and hypertension that can be clinically severe. This property is not shared by isoflurane or sevoflurane at equivalent concentration change rates. At stable maintenance concentrations, however, desflurane's cardiovascular profile closely resembles isoflurane: MAP is reduced primarily through peripheral vasodilation with relative preservation of cardiac output, and there is no sympathetic activation. This distinction — that the sympathetic surge is concentration-change-dependent, not concentration-level-dependent — is fundamental to the safe clinical use of desflurane: concentrations should be increased in small increments, and supplemental opioids or alpha-2 agonists (dexmedetomidine, clonidine) can be used to blunt the sympathetic response when larger increases are required.
Option B: Option B is incorrect because the sympathetic surge is specifically associated with rapid concentration increases, not with all concentrations above 0.5 MAC; sustained sympathetic activation throughout maintenance is not a property of desflurane and does not require routine beta-blockade.
Option C: Option C is incorrect because the surge occurs during rapid concentration increases, not during decreases; during stable maintenance desflurane does not produce more severe bradycardia or hypotension than other volatile agents — its profile at stable concentrations is similar to isoflurane.
Option D: Option D is incorrect because the sympathetic surge is triggered by the rate of concentration change, not by cumulative MAC-hours; there is no dose-accumulation threshold above which tachycardia and hypertension inevitably occur.
Option E: Option E is incorrect because desflurane's sympathetic surge is triggered by rapid concentration increases, not by co-administration with nitrous oxide; the property is intrinsic to desflurane's pharmacological interaction with airway receptors and the sympathetic nervous system during rapid concentration changes.
13. Halothane sensitizes the myocardium to catecholamine-induced arrhythmias. Which of the following correctly states the approximate epinephrine dose thresholds for ventricular arrhythmia induction under halothane compared to isoflurane, and identifies the clinical mechanism of the sensitization?
A) The threshold under halothane is approximately 5 to 6 mcg/kg and under isoflurane approximately 12 to 15 mcg/kg; the mechanism is halothane-induced alpha-1 adrenergic receptor upregulation in ventricular myocytes, increasing their sensitivity to catecholamine-mediated depolarization
B) The threshold under halothane is approximately 1.5 to 2 mcg/kg and under isoflurane approximately 7 to 10 mcg/kg; the mechanism is halothane-induced inhibition of the sympathetic nervous system's norepinephrine reuptake transporter, prolonging catecholamine exposure at adrenergic receptors in the myocardium
C) The threshold under halothane is approximately 1.5 to 2 mcg/kg and under isoflurane approximately 7 to 10 mcg/kg; the sensitization involves calcium overload in myocytes and altered automaticity of Purkinje fibers — the specialized conduction cells that generate ventricular beats — making the ventricle susceptible to ectopic rhythms at epinephrine doses that would be innocuous under isoflurane
D) The threshold under halothane is approximately 0.1 to 0.5 mcg/kg, making any epinephrine use during halothane anesthesia dangerous; the threshold under isoflurane is approximately 2 to 3 mcg/kg; the mechanism involves halothane-induced beta-2 receptor sensitization in the ventricular conduction system
E) The threshold is identical for halothane and isoflurane at approximately 3 to 4 mcg/kg; the clinical concern with halothane is not a lower arrhythmia threshold but a longer duration of sensitization that persists for 30 to 60 minutes after the agent is discontinued
ANSWER: C
Rationale:
Option C is correct. The epinephrine dose thresholds for catecholamine-induced ventricular arrhythmias under halothane versus isoflurane represent a four- to five-fold difference that is one of the most clinically important quantitative pharmacological distinctions in anesthesia practice. Under halothane, the threshold is approximately 1.5 to 2 mcg/kg — a relatively low dose easily reached with standard subcutaneous epinephrine-containing local anesthetic infiltration. Under isoflurane (and similarly under sevoflurane), the threshold is approximately 7 to 10 mcg/kg — substantially higher and providing a much greater safety margin for epinephrine use. The mechanism of halothane's sensitization involves calcium overload within ventricular myocytes and altered automaticity of Purkinje fibers, the specialized conduction cells that generate and propagate ventricular action potentials. These changes create conditions for triggered automaticity and reentry, producing ventricular ectopy, bigeminy, and potentially ventricular fibrillation at catecholamine doses that are innocuous under other agents.
Option A: Option A is incorrect because the stated thresholds are too high for halothane (5 to 6 mcg/kg vs the correct 1.5 to 2 mcg/kg) and too high for isoflurane (12 to 15 mcg/kg vs the correct 7 to 10 mcg/kg); and alpha-1 receptor upregulation is not the established mechanism.
Option B: Option B is incorrect because the threshold values are correct but the mechanism is wrong; halothane does not inhibit norepinephrine reuptake transporters — its arrhythmogenic sensitization is mediated through direct electrophysiological effects on myocardial ion channels and Purkinje fiber automaticity.
Option D: Option D is incorrect because the halothane threshold of 0.1 to 0.5 mcg/kg is far too low — at that threshold essentially any epinephrine use would be fatal, which is not the clinical reality; the correct threshold is 1.5 to 2 mcg/kg.
Option E: Option E is incorrect because the thresholds are not identical between halothane and isoflurane; the four- to five-fold difference in threshold is the defining clinical distinction, and the prolonged post-discontinuation sensitization mechanism is not an established pharmacological property of halothane.
14. Succinylcholine causes a transient increase in intracranial pressure (ICP) when administered. Which of the following correctly identifies the mechanism, the approximate magnitude, and the approximate duration of this ICP increase?
A) The ICP increase is caused by succinylcholine's direct stimulation of cerebral muscarinic receptors, producing cerebral vasodilation and increased intracranial blood volume; the increase is approximately 15 to 20 mmHg and lasts 10 to 15 minutes until the drug is metabolized
B) The ICP increase is caused by whole-body muscle fasciculations that generate afferent neural input, which transiently increases cerebral activity and cerebral blood flow; the typical increase is approximately 5 to 10 mmHg and lasts approximately 2 to 5 minutes
C) The ICP increase results from succinylcholine's inhibition of plasma cholinesterase, causing acetylcholine accumulation at central synapses and increasing cerebral metabolic rate; the increase is approximately 20 to 30 mmHg and is sustained until pharmacological reversal with neostigmine
D) The ICP increase is caused by succinylcholine-induced release of histamine from mast cells in the cerebral vasculature, producing direct cerebrovascular dilation; the increase is dose-dependent and may exceed 25 mmHg in patients with pre-existing elevated ICP
E) The ICP increase results from succinylcholine's blockade of cerebral NMDA receptors, which paradoxically increases cortical excitability by removing tonic inhibition of excitatory pathways; the increase is approximately 5 to 10 mmHg but is permanent until the NMDA receptors recover, requiring 30 to 45 minutes
ANSWER: B
Rationale:
Option B is correct. Succinylcholine causes a transient ICP increase through a peripheral mechanism: its simultaneous depolarization of all neuromuscular junctions produces whole-body muscle fasciculations. These fasciculations generate a burst of afferent neural signals from peripheral muscle spindles and sensory receptors that reach the central nervous system, transiently increasing cerebral neuronal activity and CBF. The resulting rise in intracranial blood volume elevates ICP. The magnitude is typically 5 to 10 mmHg and the duration approximately 2 to 5 minutes — transient and self-limited as the depolarizing block transitions to flaccid paralysis and the afferent input ceases. While modest in absolute terms, this transient rise may be clinically significant in patients with severely elevated ICP and exhausted intracranial compliance.
Option A: Option A is incorrect because succinylcholine does not act on cerebral muscarinic receptors to cause vasodilation; the ICP mechanism is peripheral fasciculation-mediated afferent input, not central cholinergic vasodilation; and the stated magnitude and duration are far too high.
Option C: Option C is incorrect because succinylcholine is not a cholinesterase inhibitor — it is a depolarizing neuromuscular blocking agent that is metabolized by plasma cholinesterase; cholinesterase inhibitors such as neostigmine work by a different mechanism, and acetylcholine accumulation at central synapses is not part of succinylcholine's pharmacology.
Option D: Option D is incorrect because histamine release is associated with agents such as atracurium and morphine, not succinylcholine specifically; succinylcholine does not cause significant cerebrovascular histamine release, and the stated magnitude of greater than 25 mmHg is not characteristic of succinylcholine's ICP effect.
Option E: Option E is incorrect because succinylcholine does not block NMDA receptors; it acts exclusively at nicotinic acetylcholine receptors at the neuromuscular junction; and the ICP effect is transient and fully reversible within minutes, not lasting 30 to 45 minutes.
15. Hypoxic pulmonary vasoconstriction (HPV) is a physiological reflex that diverts pulmonary blood flow away from poorly ventilated lung regions. Which of the following correctly describes the effect of volatile anesthetic agents on HPV and identifies the intravenous agent that does not share this liability?
A) Only halothane significantly inhibits HPV among the volatile agents; isoflurane, sevoflurane, and desflurane have negligible effects on HPV at clinical concentrations, making them safe choices for maintenance during one-lung ventilation
B) Volatile agents enhance HPV by increasing pulmonary vascular smooth muscle sensitivity to hypoxia; this is a beneficial effect that improves oxygenation during one-lung ventilation and is one reason volatile agents are preferred over propofol for thoracic surgery
C) Volatile agents selectively inhibit HPV only in the non-ventilated lung during one-lung ventilation; HPV in the ventilated lung is unaffected, so the net effect on oxygenation is minimal and volatile maintenance is equivalent to TIVA for thoracic cases
D) All currently used volatile anesthetic agents — isoflurane, sevoflurane, and desflurane — inhibit HPV in a dose-dependent fashion at clinically used concentrations, worsening intrapulmonary shunting and ventilation-perfusion mismatch; propofol does not inhibit HPV and is therefore preferred for maintenance during one-lung ventilation when oxygenation is marginal
E) Volatile agents inhibit HPV only at concentrations above 1.5 MAC; at standard maintenance concentrations of 0.5 to 1.0 MAC, HPV is fully preserved and propofol offers no advantage over volatile maintenance for one-lung ventilation oxygenation
ANSWER: D
Rationale:
Option D is correct. All currently used volatile halogenated anesthetic agents — isoflurane, sevoflurane, and desflurane — inhibit hypoxic pulmonary vasoconstriction in a dose-dependent fashion at clinically used concentrations. This inhibition worsens ventilation-perfusion mismatch and increases the intrapulmonary shunt fraction during one-lung ventilation by allowing blood to continue flowing through the collapsed, non-ventilated lung rather than being redirected to the ventilated lung by HPV. The result is worsened intraoperative hypoxemia, particularly when the patient's baseline reserve is already limited. Propofol does not inhibit HPV and therefore allows the physiological vasoconstriction to continue operating in the non-ventilated lung, preserving arterial oxygenation. This property is the principal pharmacological rationale for preferring propofol-based TIVA for thoracic surgery requiring one-lung ventilation when oxygenation is marginal.
Option A: Option A is incorrect because HPV inhibition is not limited to halothane; all three of the currently used volatile agents — isoflurane, sevoflurane, and desflurane — inhibit HPV at clinical concentrations, and none of them is safe in this respect relative to propofol.
Option B: Option B is incorrect because volatile agents inhibit, not enhance, HPV; enhancement of HPV would improve oxygenation during one-lung ventilation, but the opposite is true — inhibition worsens it.
Option C: Option C is incorrect because HPV inhibition by volatile agents is a generalized pulmonary effect, not selective to the non-ventilated lung; and the clinical significance of this inhibition during one-lung ventilation is substantial enough to influence agent selection.
Option E: Option E is incorrect because HPV inhibition by volatile agents occurs at clinically used concentrations of 0.5 to 1.0 MAC — not only above 1.5 MAC; the dose-dependent inhibition is present across the standard maintenance range and is clinically meaningful within it.
16. Certain volatile anesthetic agents are associated with anesthetic-induced myocardial preconditioning — a reduction in ischemia-reperfusion injury during cardiac surgery. Which of the following correctly identifies the agents with this property, the proposed cellular mechanism, and the clinical evidence supporting it?
A) All volatile anesthetic agents including halothane, enflurane, isoflurane, sevoflurane, and desflurane produce equivalent myocardial preconditioning; the mechanism is uniform beta-adrenergic receptor sensitization that improves calcium handling during ischemia; clinical evidence is limited to animal models with no human data available
B) Only desflurane produces clinically meaningful myocardial preconditioning because of its unique sympathomimetic properties during concentration changes; the mechanism is catecholamine-induced activation of alpha-1 adrenergic signaling pathways in cardiomyocytes that upregulate antioxidant defenses before bypass
C) Myocardial preconditioning is produced by nitrous oxide through NMDA receptor antagonism that reduces excitotoxic calcium influx during reperfusion; isoflurane and sevoflurane do not produce preconditioning and have no advantage over propofol TIVA for cardiac surgical cases
D) Isoflurane and sevoflurane produce preconditioning through a genomic mechanism requiring prolonged volatile agent exposure; the minimum required exposure is 4 to 6 hours, which limits its clinical applicability to long cardiac surgical procedures; the mechanism involves upregulation of heat shock proteins through transcription factor activation
E) Isoflurane and sevoflurane produce anesthetic-induced myocardial preconditioning through activation of mitochondrial ATP-sensitive potassium (KATP) channels via adenosine receptor signaling; clinical trials in cardiac surgical patients have demonstrated reductions in postoperative troponin release with volatile-agent-based maintenance compared to propofol TIVA, though the impact on hard clinical outcomes remains under investigation
ANSWER: E
Rationale:
Option E is correct. Anesthetic-induced myocardial preconditioning is a property associated specifically with isoflurane and sevoflurane among the currently used volatile agents. The proposed cellular mechanism parallels ischemic preconditioning and involves activation of mitochondrial ATP-sensitive potassium (KATP) channels. When these channels open, they help preserve mitochondrial membrane potential during ischemia, reducing the mitochondrial permeability transition that drives ischemia-reperfusion injury. Adenosine receptor signaling is one established pathway linking volatile agent exposure to KATP channel activation. The clinical evidence — from trials in patients undergoing coronary artery bypass surgery — shows that volatile anesthetic-based maintenance reduces postoperative cardiac troponin release compared to propofol TIVA, consistent with reduced myocardial injury. However, translation to hard outcomes such as mortality or myocardial infarction rate has been less consistent, and the clinical significance continues to be investigated.
Option A: Option A is incorrect because not all volatile agents produce equivalent preconditioning; halothane and enflurane are not associated with the same KATP-channel-mediated preconditioning evidence base as isoflurane and sevoflurane; and clinical human data do exist, which is why the option is incorrect in stating only animal models.
Option B: Option B is incorrect because desflurane's sympathomimetic properties during rapid concentration changes are a liability, not a cardioprotective mechanism; alpha-1 adrenergic signaling is not the established mechanism of anesthetic preconditioning; and desflurane is not the agent with the strongest preconditioning evidence.
Option C: Option C is incorrect because nitrous oxide is not the agent associated with myocardial preconditioning; its NMDA antagonism does not produce the KATP-channel-mediated protection that is the established mechanism; and isoflurane and sevoflurane do have an advantage over propofol TIVA in terms of troponin release in some cardiac surgery trials.
Option D: Option D is incorrect because anesthetic preconditioning is not a genomic phenomenon requiring 4 to 6 hours of exposure; it is an acute cellular signaling event mediated through receptor and channel activation that can be established within minutes; heat shock protein upregulation may be a related phenomenon but is not the primary established mechanism of short-term volatile agent preconditioning.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.